Page 31 - Alkermes News Today

ALKS, $31.48, Market Capitalization: $5.2 billion), a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience ...

NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / AlkermesEarlier this month, members of Alkermes' MOSAIC employee resource group and senior Human Resources leaders participated in the 17th annual ALPFA Boston's

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Companys upcoming 2023 Annual...

Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN, June 13,

Sarissa does not understand why the Alkermes independent directors refuse to add Sarissa representatives to the board Sarissa believes the addition of its representatives to the Alkermes board can... | June 13, 2023

Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial... | June 13, 2023

NEW YORK (Reuters) -Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker. The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen.

By Svea Herbst-Bayliss NEW YORK (Reuters) -Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes ...

CHICAGO — Mirvetuximab soravtansine-gynx extended survival of women with platinum-resistant ovarian cancer and high folate receptor-alpha expression, according to a study that compared the agent with investigator’s choice of chemotherapy.The antibody and microtubule inhibitor conjugate is the first novel therapy to show a survival benefit in a randomized phase 3 study among this

Alkermes (NASDAQ:ALKS – Get Rating) had its price objective hoisted by Mizuho from $36.00 to $40.00 in a research report released on Wednesday, The Fly reports. ALKS has been the subject of a number of other research reports. Stifel Nicolaus boosted their price target on shares of Alkermes to $30.00 in a research note on […]